Nature Communications (Aug 2023)

Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice

  • Marta Isidro-Hernández,
  • Ana Casado-García,
  • Ninad Oak,
  • Silvia Alemán-Arteaga,
  • Belén Ruiz-Corzo,
  • Jorge Martínez-Cano,
  • Andrea Mayado,
  • Elena G. Sánchez,
  • Oscar Blanco,
  • Ma Luisa Gaspar,
  • Alberto Orfao,
  • Diego Alonso-López,
  • Javier De Las Rivas,
  • Susana Riesco,
  • Pablo Prieto-Matos,
  • África González-Murillo,
  • Francisco Javier García Criado,
  • María Begoña García Cenador,
  • Manuel Ramírez-Orellana,
  • Belén de Andrés,
  • Carolina Vicente-Dueñas,
  • César Cobaleda,
  • Kim E. Nichols,
  • Isidro Sánchez-García

DOI
https://doi.org/10.1038/s41467-023-40961-z
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 17

Abstract

Read online

Abstract The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5 +/− B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5 +/−Myd88+/− mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5 +/− mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children.